Stockscreener 앱 받기
76.09
4.06%
2.97
시간 외 거래:
76.09
전일 마감가:
$73.12
열려 있는:
$73
하루 거래량:
2.08M
Relative Volume:
0.75
시가총액:
$12.32B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-25.03
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
+6.35%
1개월 성능:
+6.21%
6개월 성능:
+127.13%
1년 성능:
+124.19%
1일 변동 폭
$73.00
$76.31
1주일 범위
$70.69
$76.31
52주 변동 폭
$23.95
$76.78
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.09 | 11.84B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumFed Meeting & Daily Oversold Bounce Ideas - newser.com
Is Ionis Pharmaceuticals Inc. stock a defensive play in 2025Weekly Trading Summary & Weekly Return Optimization Plans - newser.com
Insider Sell: Joan Herman Sells 44,000 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Can Ionis Pharmaceuticals Inc. (ISI) stock stage a strong rebound this quarterWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionWatch List & Fast Entry Momentum Alerts - newser.com
Will Ionis Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights
How Ionis Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & AI Driven Price Forecasts - newser.com
Why Ionis Pharmaceuticals Inc. stock attracts high net worth investorsWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com
Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize
Price momentum metrics for Ionis Pharmaceuticals Inc. explained2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leaders2025 Momentum Check & Stock Portfolio Risk Management - newser.com
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News
US FDA approves Arrowhead's genetic disorder drug - Reuters
Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech
RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive
Ionis Pharmaceuticals Completes $770M Convertible Notes Offering - TipRanks
Ionis Pharmaceuticals (IONS) Price Target Increased by 10.27% to 85.25 - Nasdaq
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR) - Seeking Alpha
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) - BioSpace
Can Ionis Pharmaceuticals Inc. stock sustain free cash flow growthTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 - Yahoo Finance
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
Biogen Completes Acquisition of Alcyone Therapeutics - Benzinga
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion By Investing.com - Investing.com India
Ionis Pharmaceuticals stock rises after positive EU regulatory opinion - Investing.com
Sanofi, Lilly among winners of EU drug recommendations this week - Seeking Alpha
Ionis Pharmaceuticals (IONS) Advances with European Review for D - GuruFocus
Is Ionis Pharmaceuticals Inc. stock in correction or buying zone2025 Market WrapUp & Intraday High Probability Alerts - Fundação Cultural do Pará
Ionis Pharmaceuticals Says Dawnzera Recommended for Approval in EU for Hereditary Angioedema - MarketScreener
EU committee recommends approval of Ionis’ HAE treatment By Investing.com - Investing.com Canada
DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema - TradingView
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
1.42%
자본화:
|
볼륨(24시간):